Aster DM Healthcare declares interim dividend of ₹3/share; sets April 3 record date
Aster DM Healthcare declared an interim dividend of ₹3 per equity share for FY 2025-26. The record date for determining entitlement is April 03, 2026. The announcement details applicable TDS provisions for resident and non-resident shareholders.
The declaration of a dividend is a direct financial event for shareholders. The detailed information on TDS implications can impact the net dividend received by shareholders, making the impact medium.
The announcement is a routine declaration of an interim dividend and provides information on tax implications, which is a standard procedural update. There are no significant positive or negative financial or operational developments mentioned.
Aster DM Healthcare Limited has announced the declaration of an interim dividend of ₹3 per equity share for the financial year 2025-26. This decision was made by the Board of Directors during their meeting held on March 26, 2026.
The company has set April 03, 2026, as the record date to determine the entitlement of shareholders for this interim dividend.
Shareholders are informed about the applicable provisions relating to Tax Deduction at Source (TDS) as per the Income-tax Act, 2025. For resident members with a valid PAN, the TDS rate is 10%, with a threshold limit of ₹10,000 for individuals. Shareholders with invalid PAN or PAN not linked with Aadhar will be subject to a 20% TDS rate. Resident individuals meeting specific eligibility conditions can apply for a 0% TDS rate by submitting Form 121. For non-resident members, the withholding tax is 20% or the rate as per the applicable Double Tax Avoidance Agreement (DTAA), subject to submission of required documents. The company has also outlined procedures for TDS credit transfer to beneficial shareholders and other general information concerning tax deductions.
What to do with a filing like this
Aster DM Healthcare Limited filed this with the NSE as a statutory disclosure, categorised under dividend. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aster DM Healthcare Limited. Read the original for the full detail.